Helen Thackray
Directeur Technique/Scientifique/R&D chez BIOCRYST PHARMACEUTICALS, INC.
Fortune : 2 M $ au 30/06/2024
Profil
Helen M.
Thackray is currently the Chief Research & Development Officer at BioCryst Pharmaceuticals, Inc. She is also a Member of the Institutional Review Board at Holy Cross Hospital (Maryland).
In addition, she is an Assistant Clinical Professor at GW School of Medicine & Health Sciences.
Previously, Dr. Thackray served as an Independent Director at ImmunoGen, Inc. from 2021 to 2024.
She was also the Vice President of Clinical Product Development at Biosynexus, Inc. from 2001 to 2006.
From 2006 to 2021, she held the position of Chief Medical Officer & Senior Vice President of Clinical Development at GlycoMimetics, Inc. She was also a Member of the Institutional Review Board at the National Center for Health Statistics.
Dr. Thackray obtained her undergraduate degree from Stanford University and her doctorate from GW School of Medicine & Health Sciences.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/05/2024 | 272 139 ( 0,13% ) | 2 M $ | 30/06/2024 |
Postes actifs de Helen Thackray
| Sociétés | Poste | Début |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 19/03/2021 |
| Holy Cross Hospital (Maryland) | Corporate Officer/Principal | - |
| Gw School of Medicine & Health Sciences | Corporate Officer/Principal | 01/01/2000 |
Anciens postes connus de Helen Thackray
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Directeur/Membre du Conseil | 12/02/2024 |
| GLYCOMIMETICS, INC. | Directeur Technique/Scientifique/R&D | 19/03/2021 |
Biosynexus, Inc.
 Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD. | Corporate Officer/Principal | 01/01/2006 |
| National Center for Health Statistics | Corporate Officer/Principal | - |
Formation de Helen Thackray
| Stanford University | Undergraduate Degree |
| Gw School of Medicine & Health Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Biosynexus, Inc.
Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD. | Health Technology |
| Holy Cross Hospital (Maryland) | |
| National Center for Health Statistics | Government |
